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Reversion of the malignant phenotype of erbB2-
transformed cells can be driven by anti-erbB2/neu
monoclonal antibodies (mAbs), which disrupt the re-
ceptor’s kinase activity. We examined the biologic
effects of IFN-g alone or after anti-erbB2/neu mAb
treatment of erbB2-positive cells. IFN-g had no effect
on its own. Treatment of the tumors with anti-erbB2/
neu mAbs followed by IFN-g led to dramatic inhibi-
tion of tumor growth in vitro and in vivo with minimal
mAb dosing. Sequential therapy enhanced the ef-
fects of chemotherapy. Moreover, IFN-g with mAb
treatment of mice with IFNgR knockdown tumors
did not demonstrate marked synergistic eradication
effects, indicating an unexpected role of IFN-g on
the tumor itself. Additionally, mAb and IFN-g treat-
ment also induced immune host responses that
enhanced tumor eradication. Biochemical analyses
identified loss of Snail expression in tumor cells, re-
flecting diminution of tumor-stem-cell-like properties
as a consequence of altered activity of GSK3-b and
KLF molecules.
INTRODUCTION
The erbB or HER family of receptor tyrosine kinases consists of
erbB1 (the epidermal growth factor receptor [EGFR]/HER1),
erbB2 (p185/neu/HER2), erbB3 (HER3), and erbB4 (HER4), all
of which can form homomeric and heteromeric assemblies (Ko-
kai et al., 1989; Qian et al., 1994a). These receptor tyrosine ki-
nases participate in a variety of signal transduction cascades,
including the Ras/Raf/MEK/ERK and PI-3K/Akt pathways.
erbB2 is amplified in approximately 30% of breast cancer pa-
tients, and amplification is associated with poor prognosis and
decreased survival (Riemsma et al., 2012). In various cancers,Cell Repamplified or mutated forms of these kinases drive increased pro-
liferation, migration, survival, evasion of apoptosis, metastasis,
and resistance to chemotherapeutics and ionizing radiation.
Recognition that monoclonal antibodies (mAbs) could disable
the p185erbB2/HER2/neu tyrosine kinase receptor complex and also
lead to reversal of the malignant phenotype challenged dogma
that transformed cells could only progressively become more
abnormal (Drebin et al., 1985; Schechter et al., 1984). Reversal
of the malignant phenotype by anti-erbB2 mAb begins rapidly
within 24 hr of mAb binding (Drebin et al., 1986; Lee et al.,
2012; O’Rourke et al., 1997; Qian et al., 1994b) and occurs
with downregulation of p185erbB2/neu receptor tyrosine kinase
proteins, causing diminished enzymatic activity (Drebin et al.,
1986, 1988a; Furuuchi et al., 2007; Sliwkowski and Mellman,
2013; Wada et al., 1990; Zhang et al., 2007). These mechanistic
events altering phenotype occur more dramatically with the in-
clusion of a second antibody, which more completely disables
erbB2/neu kinase function (Drebin et al., 1988b; Furuuchi et al.,
2007).
Tumor eradication that occurs in some partially syngeneic
erbB2/neu models also displayed a role for CD8+ T cells, macro-
phages, and natural killer cells (Park et al., 2010; Stagg et al.,
2011). Cytokines derived from CD8+ T cells and other cell types
also contribute in certain tumor models (Park et al., 2010; Stagg
et al., 2011). IFN-g, a cytokine that plays diverse roles in innate
and adaptive immune response, has been implicated in tumor
immune responses. Stagg et al. (2011) demonstrated activity
of both type I and II IFNs in mediating anti-erbB2 mAb functions
in vivo in non-syngeneic tumor host systems.
Early biochemical studies indicated that IFN-g could limit
p185erbB2/neu expression at the mRNA level (Marth et al., 1990)
in some tumor lines. Conversely, IFN-g alone was thought to in-
crease erbB1 (EGFR) levels (Hamburger and Pinnamaneni, 1991)
and TGFa secretion through increased EGFR activity (Uribe
et al., 2002) as well as to promote malignant growth of certain
murine tumors (Beatty and Paterson, 2000). IFN-g may also
contribute to local environmental angiogenic effects (Coughlin
et al., 1998). Historically, IFN-g was one of the first recombinantorts 12, 2049–2059, September 29, 2015 ª2015 The Authors 2049
Figure 1. Anti-erbB2 Monoclonal Antibody
and IFN-g Act Directly on HER2-Positive
Breast Cancer Cells
(A) SK-BR-3 cells were treated with regimens of
anti-erbB2 mAb (4D5) and IFN-g at the indicated
concentrations. Protocols described as IFN-
g 4D5+IFN-g were treated with the indicated
dose of IFN-g for 4 days and then the indicated
dose of IFN-g plus 4D5 for an additional 4 days.
Protocols described as 4D5 4D5+IFN-g were
treated with 4D5 for 4 days and then the indicated
dose of IFN-g plus 4D5 for an additional 4 days. All
other treatment groups were treated as indicated
for 8 days. Following a total of 8 days, an MTT
assay was performed. Data were normalized to the
cIgG group. Bar graphs represent the mean ± SD
of a typical experiment (n = 5).
(B) SK-BR-3 cells were treated as indicated, and
MTT assays were performed every 2nd day. Data
were normalized to the cIgG group on day 0. Data
points represent the mean ± SD of a typical
experiment (n = 6).
(C) SK-BR-3 cells were seeded in a 0.2% agar solution containing the indicated treatments, which was layered over a 0.8% agar solution. After 14 days in culture,
viable foci were visualized following incubation with MTT solution.
(D) Foci from (C) were quantified using NIH-endorsed software (ImageJ). Bar graphs represent the mean ± SD of a typical experiment (n = 3 or 4; n.s., not
significant; *p < 0.05; **p < 0.01; ***; p < 0.001).
See also Figure S1.cytokines tested as a single agent in trials of multiple human can-
cers but led to few if any beneficial outcomes. Thus, clinical
efforts using IFN-g as a primary single therapeutic for most ma-
lignancies have not been pursued (Krigel et al., 1985).
Certain proteins relevant to phenotypic developmental
changes in stem cells and transformed cells have been
described (Zheng and Kang, 2014). The transcriptional repressor
Snail is essential for gastrulation and mesoderm formation dur-
ing mammalian development (Carver et al., 2001). Snail levels in-
crease in transformed cells. Elevated levels of Snail contribute to
tumor recurrence in vivo in erbB2/neu murine models, and levels
of Snail may be relevant to relapse-free survival patterns in
breast cancer patients (Moody et al., 2005). Slug transcriptional
proteins may similarly function together to induce a stem-like
phenotype in mammary cells in addition to maintaining tumor
and metastatic properties (Guo et al., 2012).
Glycogen synthase kinase 3-beta (GSK3-b), while negatively
modified by Akt1, post-translationally regulates Snail through
site-specific phosphorylation. Regulatory post-translational
phosphorylation modifications alter Snail’s subcellular localiza-
tion and stability. Specifically, GSK3-b phosphorylates Snail on
six serine residues (serines 97, 101, 108, 112, 116, and 120), en-
compassing two motifs that promote translocation from the nu-
cleus to the cytoplasm and b-TRCP-mediated ubiquitination and
degradation (Feinberg et al., 2005; Zhou et al., 2004). Zheng and
Kang (2014) suggested Snail affects phenotypic changes in can-
cer cells and described epithelial to mesenchymal changes in
both neu- and ras-transformed cells.
Products of activated immune cells such as IFN-g have been
shown to enhance the expression of the KLF4 transcription fac-
tor, which itself can repress Snail transcription (Feinberg et al.,
2005; Yori et al., 2011). KLF4 overexpression induces macro-
phage activation markers whereas KLF4 knockdown markedly2050 Cell Reports 12, 2049–2059, September 29, 2015 ª2015 The Amodulates the ability of IFN-g to render those effects. Transfec-
tion of KLF4 attenuated primary tumor growth as well as
affecting development of metastatic lesions. erbB-targeted im-
mune therapy processes that govern Snail protein functions
have not been described.
Here, we revealed that combinations of erbB2-targeted mAb
and IFN-g, but not IFN- a or b, can modify Snail expression
and contribute to phenotypic reversion and cell viability by
altering GSK3-b activity and KLF4 expression in breast tumors.
We have also extended these efforts in vivo in therapeutic and
prevention models. Our findings provide better and less-toxic
human breast cancer therapeutic strategies.
RESULTS
Sequential and Concurrent mAb 4D5 and IFN-g
Activities on erbB2+ Breast Cancer Cells
erbB2-transformed human SK-BR-3 breast cancer cells were
treated with IFN-g and anti-erbB2 mAb (4D5) or control IgG
(cIgG) at different times. Cells simultaneously exposed to both
4D5 and IFN-g for 8 days were included. Pre-treatment with
4D5 for 4 days followed by the addition of IFN-g caused a greater
reduction in cell viability than pre-treatment with IFN-g followed
by addition of 4D5. Prolonged co-treatment with 4D5 and IFN-g
resulted in greater reduction in cell viabilities (Figure 1A).
Kinetics of the sensitizing effect was examined using an inter-
mediate dose of IFN-g (10 ng/ml). Dramatic reduction in cell
viability was noted over an 8-day time course in the presence
of 4D5, which could be augmented with the inclusion of IFN-g
(Figure 1B). These in vitro studies were performed with a single
treatment of IFN-g, 4D5, or IFN-g+4D5 administered the day
following cell seeding (i.e., day 0). Immortalized but untrans-
formed MCF10A cells were refractory to 4D5 alone or inuthors
Figure 2. Effects ofmAb Therapy Combined
with IFN-g In Vitro
Different cell types were treated as indicated, and
MTT assays were performed every 2nd day. Data
were normalized to the cIgG group on day 0. Data
points represent the mean ± SD of a typical
experiment (n = 6). See also Figure S1.combination with IFN-g (Figure S1A). These latter data indicate
that the combined ordered effects are manifest only on cells
that have acquired malignant properties.
The effects of this treatment regimen were examined in pre-
vention of foci formation in soft agar assays. Treatment with
4D5 produced a dramatic reduction in the formation of foci in
soft agar compared to cIgG and IFN-g alone as demonstrated
by a greater percentage of foci less than 20 pixels as well as
fewer foci greater than 20. Addition of IFN-g produced a greater
percentage of foci under 20 pixels than 4D5 alone and a reduced
percentage of foci greater than 20 pixels compared to 4D5 alone
(Figures 1C and 1D).
Collectively, these studies established that disabling the
p185erbB2 kinase with mAb followed by IFN-g produced the
most-significant phenotypic and viability effects on breast tumor
cells.
Phenotypic Effects of mAb and IFN-g on Other Cell
Types
We speculated that some erbB1 tumors might not be influenced
by ectodomain-binding monoclonals because of the action of
IFN-g on EGF/TGF expression (Uribe et al., 2002) or by muta-
tions that limit the effects of targeting mAbs. U87 cells, which
are driven by EGFR VIII that lacks portions of the extracellular
domain of the EGFR, failed to respond to the anti-EGFR mAb
C225 (Figures S1B and S1C). However, A431 cells, which lack
erbB2 but express EGFR holoreceptor homomeric dimers, simi-
larly responded to dose-dependent increases of IFN-g in the
presence of C225 (Figures 2A and S1D) in a similar manner to
erbB2/neu-transformed cells.
The erbB2+ breast cancer cell lines MDA-MB-453 and BT-474
display distinct phenotypes from the SK-BR-3 cells. MDA-MB-
453 and BT-474 were inhibited by 4D5 mAb, and MDA-MB-
453 cell viability was further affected by the inclusion of IFN-gCell Reports 12, 2049–2059, Sep(Figure 2B). Triple-negative breast cancer
cells, MDA-MB-231, responded mini-
mally to C225 mAb but also responded
to IFN-g alone (Figure 2C). IFN-g and a
single mAb treatment did not have
additive effects on BT-474 cell growth
(Figure 2D).
The PI3-K/AKT/GSK3b Snail
Pathway Can Be Modified by mAb
and IFN-g or Kinase Inhibitors Such
as Lapatinib
SK-BR-3 cells were treated with the dual
EGFR/HER2 small-molecule tyrosine ki-
nase inhibitor lapatinib or 4D5 and C225alone and in combination to determine which signaling pathways
were affected by disabling erbB familymembers. Lapatinib treat-
ment inactivated both the Akt and MAPK pathways as antici-
pated (Figure S2A). 4D5, but not C225, dominantly inactivated
Akt but did not affect MAPK activities. Combinations of 4D5
and C225 to disable heteromeric kinase complexes also inacti-
vated Akt in SK-BR-3 cells. Disabling erbB2 in these cells acti-
vated phosphorylated GSK3-b. We also found that treatment
with 4D5 (but unexpectedly not with C225 alone) reduced Snail
levels selectively (Figure S2A).
We next compared the lapatinib response in SK-BR-3 and
MDA-MB-453 cells. Lapatinib treatment diminished Akt activity
in both cell lines and, to a lesser extent, MAPK signaling (Fig-
ure S2B). Lapatinib induced a dose-dependent reduction in
Snail. Antagonism of PI3-kinase and AKT1/2 inhibitor in SK-
BR-3 cells revealed a reduction in Snail, but not Slug (Figures
S2C and S2D).
We then determined whether the combination of IFN-g and
anti-erbB2 mAb could further reduce Snail protein levels. SK-
BR-3 cells were treated with cIgG or 4D5 and increasing doses
of IFN-g. We found an IFN-g dose-dependent reduction of Snail
only in the presence of 4D5 (Figure 3A). We found that GSK3-b
activation is enhanced by IFN-g in the presence of 4D5
compared to IFN-g-treated samples in the presence of cIgG.
Slug content was initially unaffected (Figure 3A); however, by
3 days, treatment led to reduction of Slug levels (Figure S2E).
Combination of 4D5 and C225 in the presence of IFN-g pro-
duced the most-dramatic reduction in Snail and also reduced
Slug content (Figure 3B).
The notion that simultaneous mAb inhibition of HER2 and
EGFR could reduce Snail and Slug prompted us to examine
whether small-molecule kinase inhibitors such as lapatinib treat-
ment could be modified by IFN-g. SK-BR-3 cells treated with
increasing doses of lapatinib and IFN-g showed reduced Snailtember 29, 2015 ª2015 The Authors 2051
Figure 3. Inclusion of IFN-g Potentiates the
erbB2-Disabling-Caused Snail Degradation
(A) SK-BR-3 cells were treated for 48 hr with cIgG,
4D5, or IFN-g as indicated and subjected to
western blotting.
(B) SK-BR-3 cells were treated for 2 days with
cIgG, 4D5, C225, or IFN-g as indicated, and the
expression of Snail and Slug were detected by
western blotting.
(C) SK-BR-3 cells were treated for 24 hr with
vehicle (0.001% DMSO), three doses of lapatinib,
or IFN-g (two doses) as indicated. In all instances,
equal amounts of lysate were separated by SDS-
PAGE, transferred, and immunoblotted with the
indicated antibodies. b-actin is used as a loading
control.
See also Figure S2.and Slug levels (Figure 3C). Thus, erbB receptors erbB2 and
erbB1 (EGFR), functioning as heteromeric kinases, stabilize Snail
and Slug, and combinatorial receptor-disabling events in the
presence of IFN-g provide optimal signal disruption and degra-
dation of these proteins.
IFN-a and IFN-b Do Not Induce the Phenotypic Changes
Seen with IFN-g
A recent study demonstrated that inclusion of IFN-b with an
EGFR antibody produced a more-potent anti-tumor effect than
EGFR antibody alone (Yang et al., 2014). Therefore, we
compared IFN-b with IFN-g in the presence and absence of
4D5. Unexpectedly, we found that IFN-b dramatically reduced
Snail, even in the absence of 4D5 treatment (Figure 4A). Surpris-
ingly, we found that IFN-b was cytotoxic to tumor cells even at
small doses in the absence of 4D5 (Figure 4B). IFN-g treatment
of MCF10A cells caused minimal changes to cell viability,
whereas even low doses of IFN-b were cytotoxic to these cells
(Figure 4C). In vivo studies also failed to determine effects of
IFN-a and anti-erbB2 mAb (data not shown). Therefore, we
believe that, under these conditions, only IFN-g acts to complete
phenotypic reversion engendered by anti-erbB2 mAb therapy.
Reduction of Snail Protein Is Triggered by Elevated
GSK3-b and Occurs Primarily through Altered
Proteasome-Mediated Degradation
Snail is predominantly degraded through the proteasome and, to
a lesser extent, the lysosome. We initially tested the role of2052 Cell Reports 12, 2049–2059, September 29, 2015 ª2015 The AuthorsGSK3-b using the small-molecule inhibi-
tor. Inhibition of GSK3-b in the presence
of the co-treatment regimen resulted in
a dose-dependent rescue of Snail but
produced no change in Slug content (Fig-
ure 5A). Proteasome inhibitor MG-132
inhibited the co-treatment-mediated
reduction of Snail in a dose-dependent
manner, also with no change in Slug con-
tent (Figure 5B). Conversely, inhibition of
lysosomal function with chloroquine was
not able to rescue the 4D5- and IFN-g-mediated degradation of Snail (Figure S3A). Therefore, we
conclude that 4D5- and IFN-g-mediated Snail degradation is
mediated primarily through the proteasome.
Next, we examined whether there was a direct effect on snail
levels caused by this ordered treatment in GSK3-b knockdown
cells. Although GSK3-b was knocked down in SK-BR3 cells
by shRNA vectors, Snail expression was still significantly
decreased (Figure S3B).
We consider other pathways are also affected by Snail func-
tions. Moral et al. (2009) reported that KLF4 expression patterns
were increased in tumor samples frommicewith hyper-activated
Akt.We examined the effects of ordered and combined targeting
antibody and IFN-g on KLF4 levels in SK-BR-3 cells stably trans-
fected with GSK3-b shRNA. The ability to alter Snail functions
was directly linked to KLF4 levels and GSK3-b (Figure S3B).
Because treatment with 4D5- and IFN-g-activated GSK3-b
and active GSK3-b promotes Snail degradation, expression of
a version of Snail with theGSK3-b phosphorylation sitesmutated
to alanines should prevent this degradation. We transiently ex-
pressed empty vector (EV), HA-tagged Snail wild-type (WT) (Ka-
jita et al., 2004), and HA-tagged Snail with serines 97, 101, 108,
112, 116, and 120 mutated to alanine (6SA; Zhou et al., 2004) in
SK-BR-3 cells. ExogenousWTSnail was degradedwhereas 6SA
Snail was largely resistant to 4D5- and IFN-g-induced proteaso-
mal degradation in the nuclear fraction (Figure 5C). In cells trans-
fected with the EV control, we observed Snail in the cytoplasm
only when the cells were treated with both 4D5 and IFN-g (Fig-
ure 5C), indicating that both treatments are required for Snail
Figure 4. IFN-g, but Not IFN-b, Requires the
Inclusion of Anti-erbB2 mAb
(A) SK-BR-3 cells were treated for 1 day with cIgG,
4D5, IFN-b, or IFN-g as indicated. Equal amounts
of lysate were separated by SDS-PAGE, trans-
ferred, and immunoblotted with the indicated
antibodies. b-actin is used as a loading control.
Shown is a representative western blot of a typical
experiment.
(B) SK-BR-3 cells were treated as indicated, and
MTT assays were performed every 2nd day. Data
were normalized to the cIgG group on day 0. Data
points represent the mean ± SD of a typical
experiment (n = 6).
(C) MCF10A cells were treated as indicated for
8 days. Vehicle control for IFN-g experiments was
performed by addition of media whereas vehicle
control for IFN-b experiments was a vehicle
(50 mM NaOAc [pH 5.5] containing 0.1% BSA).
Following treatment, an MTT assay was used to
assess viability. Data were normalized to IFN-g
control values. Bar graphs represent the mean ±
SD of a typical experiment (n = 5; **p < 0.01;
***p < 0.001).translocation to the cytoplasm. In addition, Snail knockdown in
SK-BR-3 cells increases the effects of 4D5-targeted therapy
on anchorage-dependent cell growth patterns (Figures S3C
and S3D). These results indicate that snail degradation that is
promoted by 4D5 plus IFN-g-ordered treatment occurs through
the GSK3-b/proteasome pathway and decreasing Snail levels
are important for targeted therapy.
Effects of mAb and IFN-g In Vivo: Ordered Combinations
Reduce the Need for Large Amounts of Targeting mAb
mAb 7.16.4 is biologically active in vivo and in vitro. In vitro mAb
7.16.4 is active against cells transformed with the rat or human
erbB2/neu oncogene and disables the p185erbB2/neu kinase,
leading to diminished downstream p185erbB2/neu signaling (Dre-
bin et al., 1986; Zhang et al., 1999). We as well as others exam-
ined various optimized doses of anti-erbB2/neu mAb therapy.
Fivemilligrams per kilogram of 7.16.4mAb have been used intra-
venously (Drebin et al., 1986) and/or on every other day intraper-
itoneally in therapeutic studies of tumor growth (Du et al., 2013;
Stagg et al., 2011).
We examined whether reduced amounts of mAb could
be used if IFN-g was provided after therapy was initiated. As
shown in Figure 6A, when entirely syngeneic MMTV-neu trans-
genic mice were treated with a suboptimal dose of 7.16.4
(1.5 mg/kg), the mAb was unable to substantially inhibit the
growth of H2N113 tumors. IFN-g treatment alone also failed to
significantly inhibit tumor growth. However, the combination of
suboptimal amounts of 7.16.4 and IFN-g completely arrested
the growth of H2N113 tumors. Importantly, the pattern of the
data in Figure 6A was reminiscent of the in vitro tumor cell prolif-
eration kinetics in Figure 1B. Finally, histologic examination of
the tumor tissues after treatment revealed significant necrosis
only in mice treated with both 7.16.4 and IFN-g (Figure S4A).Cell RepTo examine whether IFN-gwas targeted to tumor cells directly
or to host elements in the vicinity of the tumor, we limited the
expression of the IFN-g receptor on these tumor cells. Using
shRNA, we created an IFN-g receptor knockdown species of
theH2N113cell line:H2N113 (IFNgRKD;Figure 6B). The reduced
expression level of IFN-g receptor was confirmed in several
distinct ways (Figures S4B–S4D). IFNgRKD tumor cells form pro-
gressively growing tumors. Nevertheless, treatment with subop-
timal mAb doses generated only a modest growth reduction of
IFNgRKD tumor growth (Figure 6B). IFN-g had no effect on its
own against tumors that had diminished IFN-g receptor levels.
Ordered Therapy Also Affects Myeloid-Derived
Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) are phenotypically
CD45+, CD11b+, and GR-1+. Co-treatment with suboptimal
7.16.4 and IFN-g led to reduction of MDSC populations invading
tumor tissues (Figure 6C). We noted that there were limited but
comparable numbers of Foxp3 cells in control and treated
animals.
Because we have determined that both mAb and IFN-g must
interfere with tumor cells directly, we evaluated the chemo-
attractant effects of molecules elaborated by tumor cells on
MDSCs that might be affected by the combined treatment.
MDSCs isolated from the spleen of tumor-bearing mice were
placed into the apical chamber of a transwell system. Condi-
tioned medium from H2N113 cells treated directly with mAb,
IFN-g, or their combinations were tested for their ability to attract
MDSCs to migrate into the basolateral chamber. As shown in
Figure 6D, 7.16.4 alone slightly reduced the tumor-promoted
migration, but co-treatment of the tumor cells with 7.16.4 and
IFN-g blocked MDSCmigration. IFN-g alone had no appreciable
effects.orts 12, 2049–2059, September 29, 2015 ª2015 The Authors 2053
Figure 5. Anti-erbB2 and IFN-g Degrade
Snail through the GSK3-b/Proteasome
Pathway
SK-BR-3 cells were treated with cIgG, 4D5, and
IFN-g as indicated for 2 days.
(A) During the final 8 hr of treatment, vehicle
(0.01% DMSO) or the indicated doses of the
GSK3-b inhibitor CHIR99021 were added.
(B) During the final 8 hr of treatment, vehicle
(0.025% ethanol) or the indicated doses of the
proteasome inhibitor MG-132 were added.
(C) SK-BR-3 cells were transfected with either
empty vector (EV), wild-type (WT) Snail, or Snail
with serines 97, 101, 108, 112, 116, and 120
mutated to alanines (6SA). The day after trans-
fection, cytoplasmic and nuclear fractions were
prepared from these cells. In all instances, equal
amounts of lysate were separated by SDS-PAGE,
transferred, and immunoblotted with the indicated
antibodies. b-actin and Ku70 (nuclear fraction)
were used as loading controls. Shown are repre-
sentative western blots of typical experiments.
See also Figure S3.Enhanced Role for IFN Type II Signals in erbB Cytolytic
Immune Responses
Several research studies have suggested a role for T cells (Park
et al., 2010; Stagg et al., 2011, 2012) in some component of the
host response to 7.16.4 mAb. We used suboptimal mAb and
IFN-g in syngeneic systems and collected splenic effector
CD8+ T cells from each treatment group to investigate their activ-
ity againstH2N113cells. The combination therapy group showed
modest but definite effector T cells activity against p185erbB2/neu-
positive tumors. IFN-g alone had negligible effects (Figure S4E).
These data support the notion that minor antigens become
more relevant when we use mAb and IFN-g ordered therapy.
Macrophages may contribute to the effector response. Two
types of functional macrophages have been proposed to infil-
trate the tumor microenvironment, and such invasion is pro-
moted by molecules elaborated directly or indirectly by tumor
cells. We examined tumors for invading anti-inflammatory,
pro-tumor M2 and pro-inflammatory, cytolytic anti-tumor M1
types. mAb 7.16.4 and IFN-g increased M1 cell accumulation
within adjacent areas of the tumor, and animals treated with
this combination therapy had the highest M1 frequency (Figures
S4F–S4H).
Based on these data, we suggest that immune regulation is
affected indirectly by the dominant effect of mAb and IFN-g on
the tumor itself. Ordered therapy reduces tissue and immune
regulatory cell activity in the microenvironment, and this reduc-
tion is permissive for effector T cells to act on phenotype-
reversed tumor cells.
In Vivo Evidence of Modification of Stem Cell
Characteristics by mAb and IFN-g
Molecular analyses in vitro revealed that the ordered treatment
of breast tumor cells with anti-erbB2/neu mAb and IFN-g dimin-2054 Cell Reports 12, 2049–2059, September 29, 2015 ª2015 The Aished expression of Snail proteins, whichmediates stem-cell-like
properties. ALDH1 expression patterns also define cancer stem
cell phenotypes, and its expression correlates with breast can-
cer prognostic features (Douville et al., 2009; Ginestier et al.,
2007). We compared tumors at the end of treatment for ALDH1
levels. Co-treatment with 7.16.4 and IFN-g treatment reduced
the expression of ALDH1 in p185erbB2/neu tumors (Figure 6E).
Growing tumor cells were also studied for expression patterns
of Snail. We noted a reduced level of Snail protein in tumors
undergoing eradication as a consequence of mAb and IFN-g
therapy in vivo (Figure 6E). These studies directly correlate with
in vitro findings described in Figure 1, examining anchorage-
dependent and independent effects of combinations of anti-
erbB mAb and IFN-g.
Ordered mAb and IFN-g Therapy Can Prevent Breast
Cancer Tumorigenesis and Synergistically Inhibits
Tumor Growth with Chemotherapy
To determine whether these therapeutic effects were relevant to
prevention of tumor development (adjuvant use of this combina-
tion), we chose to examine a model we have previously
described, using small tumor inocula. We examined the effects
of treatment of MMTV-neu female mice with combinations of
7.16.4 and 7.9.5 mAb, with or without IFN-g, in animals im-
planted with small tumor inocula to mimic incipient tumors. We
noted a dramatic reduction when IFN-g was incorporated in
the treatment protocol. As can be seen in Figure 6F, we were
able to limit tumor growth in this prevention model with minimal
amounts of dual targeting mAb. These studies indicate that ani-
mals treated with ordered therapy of mAb and IFN-g can mount
potent intrinsic cytotoxic elimination of small numbers of
incipient tumor cells. These data support previous studies
showing a delayed emergence of tumors when mAb specificuthors
Figure 6. Synergistic Activity of Anti-erbB2/
neu Antibody and IFN-g
(A) Implanted H2N113 tumors were treated with
control IgG, IFN-g (three times per week), 7.16.4
(twice per week), or the combination of IFN-g and
7.16.4.
(B) IFN-g receptor was knocked down by shRNA in
H2N113. The resulting tumor cells (1 3 106) were
injected subcutaneously into MMTV-neu mice and
treated similarly as in (A). Data represent mean +
SEM. A Student’s t test was performed to compare
the difference in the tumor size of different treat-
ment groups. *p < 0.05 and **p < 0.01 compared
with control; #p < 0.05 and ##p < 0.01 compared
with the 7.16.4 group; &p < 0.05 and &&p < 0.01
compared with the IFN-g group.
(C) H2N113 tumors from each group of mice
treated as indicated were obtained after treatment
for Figure 6A was finished. Tumor-infiltrated
MDSCs were isolated and compared using
CD11b, Gr-1, and CD45 antibody by FACS. *p <
0.05 and **p < 0.01 as compared with the IgG-
treated group.
(D) In vitro migration assay. H2N113 cells were
seeded on 12-well plate and cultured until sub-
confluent. Cells were then treated with control IgG
(10 mg/ml), 7.16.4 (10 mg/ml), IFN-g (10 IU/ml), and
7.16.4 and IFN-g, and conditioned media were
collected at day 3 of culture. Migration of MDSC
was measured by the Transwell system (pore size:
4 mm). MDSCs were isolated from spleens of tu-
mor-bearing mice and then seeded in the apical
chamber. Conditioned media were then placed in
the basolateral chamber and incubated for 3 hr.
The cells that migrated to the bottom chamber
were collected and counted. Fresh medium was
used as control (medium). #p < 0.05 (compared
with either 7.16.4- or IFN-g-treated group).
(E) In vivo co-treatment significantly reduced the
expression of ALDH1 in the tumor. Tumors from
each group of mice treated as indicated were ob-
tained after treatment for Figure 6A was finished.
Each lysate was adjusted to 10 mg/lane and
examined for Snail and ALDH1 expression by
western blot. b-actin was used as the loading
control. Shown are representative western blots of
typical experiments.
(F) H2N113 tumor cells (0.25 3 106) were injected
subcutaneously into both sides of the back of 6- to
10-week-old MMTV-neu mice at day 0. Mice were
treated with control PBS, 7.9.5, and 7.16.4 (0.625 mg/kg each) or the combination of IFN-g, 7.9.5, and 7.16.4 twice per week from day 1.
(G) H2N113 tumor cells (1 3 106) were injected subcutaneously into MMTV-neu mice similarly as in (A). Mice were treated with control PBS, 7.16.4 (1.5 mg/kg
twice per week), and docetaxel (5.5 mg/kg twice per week), 7.16.4 and IFN-g (5 3 105 IU/kg three times per week), or the combination of IFN-g, 7.16.4, and
docetaxel. Data represent mean + SEM. A Student’s t test was performed to compare the difference in the tumor size of different treatment groups.
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 compared with control; #p < 0.05 and ##p < 0.01 compared with the 7.16.4 and docetaxel group; &p < 0.05
and &&p < 0.01 compared with the 7.16.4 and IFN-g group. See also Figure S4.for erbB2/neu was used as an adjuvant therapy in mouse pre-
vention studies (Finkle et al., 2004; Katsumata et al., 1995).
To extend these studies to a clinical context, we added doce-
taxel in sub-therapeutic quantities to evaluate whether potent tu-
mor inhibition with small amounts of phenotype-reversing mAb
would also limit the required genotoxic amounts of currently em-
ployed chemotherapy (Figure 6G). Treatment with 7.16.4 fol-
lowed by IFN-g and docetaxel led to inhibition of tumor growthCell Repcompared with other groups despite using suboptimal doses of
both anti-erbB antibody and chemotherapy. Our conclusion is
that optimizing phenotype reversion represents a critical element
in the evolution of precision drug therapy of breast carcinoma.
IFN-g Dramatically Promotes Tumor PD-L1
We observed aggressive tumor growth in IFN-g-alone-treated
mice. This observation is also consistent with why IFN-g aloneorts 12, 2049–2059, September 29, 2015 ª2015 The Authors 2055
Figure 7. PD-L1 Expression Is Increased in
Tumors Treated with IFN-g
(A) Western blotting was performed with anti-PD-
L1 antibody with the tumors from each indicated
group of mice after treatment in the same way as
Figure 6A.
(B) FACS analysis of PD-L1 expression in tumor
cells from control IgG and 7.16.4 + IFN-g-treated
mice. Tumor cells are gated as CD45 large size
cells, which we confirmed most of them are tumor
cells by 7.16.4 antibody. **p < 0.02.
(C) Administration of anti-PD-L1 antibody with the
ordered therapy. Mice were treated with control
PBS, 7.16.4 (1.5 mg/kg three times per week) and
anti-PD-L1 (5 mg/kg twice per week), 7.16.4 and
IFN-g (5 3 105 IU/kg three times per week), or the
combination of IFN-g, 7.16.4, and anti-PD-L1.
Data represent mean + SEM.is not useful for cancer therapy (Zaidi and Merlino, 2011). Stagg
et al. (2011) showed that treatment with IFN-g induces PD-L1
expression, and it is possible that PD-L1 acts as a negative im-
mune regulator induced by IFN-g treatment alone. As shown in
Figure 7A, IFN-g induced PD-L1 expression in IFN-g-treated tu-
mor tissues. FACS analysis showed this upregulation also oc-
curs in tumor cells themselves (Figure 7B). To determine whether
PD-L1 can be further targeted with ordered mAb and IFN-g ther-
apy, we used anti-PD-L1 antibody along with 7.16.4 and IFN-g.
As expected, administration of anti-PD-L1 antibody with 7.16.4
and IFN-g caused the most-significant tumor regression in those
groups (Figure 7C). These results indicate that PD-L1 can repre-
sent an additional target, especially when used with mAb and
IFN-g ordered therapy.
DISCUSSION
Therapeutics that target p185erbB2/HER2/neu are effective for re-
straining human malignant disease but are rarely curative.
Disabling of the p185erbB2/neu kinase complex leads to pheno-
typic reversal of malignant properties but is incomplete and sub-2056 Cell Reports 12, 2049–2059, September 29, 2015 ª2015 The Authorsject to further modification (Drebin et al.,
1986; Lee et al., 2012; O’Rourke et al.,
1997; Wada et al., 1990). This phenotypic
state is more sensitive to genotoxic
damage by chemotherapeutic and radia-
tion effects or immune-mediated lytic
processes. Our studies identified a sec-
ond transition process that occurs
after mAb-mediated downregulation of
p185erbB2/neu proteins from the cell sur-
face, which can be induced by IFN-g.
This transition involves a role of transcrip-
tion factors such as Snail known to be
relevant to cancer stem cell features.
IFN-g alone, without the first reversion
step, is ineffective in being able to induce
a malignant phenotype reversion or
change in Snail levels.We describe a dramatic and almost complete arrest of tumor
growth even with suboptimal doses of anti-erbB2/neu mAb
when IFN-g is included and in vivo. Because IFN-g enhances
antibody effects at very low doses, this approach may improve
targeted therapy effectiveness in tissues where only low levels
of antibody might penetrate. Dramatic tumor inhibitory effects
can be also accomplished with minimal amounts of targeting
mAb and IFN-g followed by chemotherapeutics (docetaxel).
These studies identify a benefit of this rational approach to pre-
cision medicine that will be accompanied by lessened toxicity
during tumor treatment.
The effect of mAb and IFN-g are a consequence of phenotypic
reversal changes on the tumor itself as well as effects of IFN-g on
host elements. The synergistic effects of mAb and IFN-g were
lost when tumor cells with reduced IFN-g receptor levels were
targeted. At the microenvironment level, we noticed a reduction
of regulatory cells that limit immune reactions by suppressing
functions of immune cells. Tumor-elaborated chemo-attrac-
tants, which recruit regulatory cells, were diminished upon
ordered treatment of tumor cells with mAb and then IFN-g. We
have been unable to document any comparable phenotypic
activity in the well-established models we use when IFN-a
or IFN-b were used (in vivo or in vitro, respectively) rather
than IFN-g.
Contributions of regulatory MDSCs in the local tumor environ-
ment may be important in limiting immune elimination of breast
tumors, and their activity is diminished with ordered mAb and
IFN-g therapy. Enhanced accumulation of M1-type macro-
phages in the local tumor environment in situations using
combined mAb and IFN-g therapy was observed. Modest
enhancement of cytolytic T cells active against erbB2 tumors
was also noted. Together, these data support an observable
contributory role for the immune system in targeted therapy
and a role for IFN-g in enhancing immune eradication of erbB
tumors that have undergone phenotype reversal.
ALDH1 is diminished in tumor cells treated in vivo with com-
binedmAb and IFN-g therapy. Elevation of ALDH1 enzyme levels
correspond to erlotinib resistance in erbB1 (EGFR)-mutated hu-
man tumors (Corominas-Faja et al., 2013). Thus, metabolic
changes occur within tumor cells with stem-cell-like properties
that are amenable to manipulation by phenotypic reversion
best promoted by anti-p185erbB2/neu mAb and by IFN-g. Conse-
quently, tumor tissues should be examined diagnostically for
expression of IFN-g receptor and aldolase in situations in which
targeted therapy might be administered.
IFN-g is a cytokine that is considered to activate anti-tumor
immunity with its cytostatic/cytotoxic activities. However, there
are few IFN-g-defined beneficial outcomes clinically when
used alone. Thus, clinical efforts using IFN-g as a primary single
therapeutic for most malignancies have not been pursued (Krigel
et al., 1985). We found, as has been reported by others, that
IFN-g treatment increases PD-L1 expression in the tumor tissues
and cells. The PD-1/PD-L1 pathways along with CTLA-4 repre-
sent elements of a checkpoint pathway and contribute to regu-
lating tumor immunity (Ott et al., 2013). Interestingly, the fact
that PD-L1 expression is increased by IFN-g in tumor site/cells
may be relevant to the success of the ordered therapy we have
described.
Combining targeted therapy with immune therapy in an
ordered way may lead to a greatly reduced need for the mAb
components and the genotoxic chemotherapeutics needed to
treat humans with erbB-caused cancers.
EXPERIMENTAL PROCEDURES
Cells and Reagents
See Supplemental Information.
Lysate Preparation and Western Blotting
Cells were lysed in a RIPA-based buffer with protease inhibitors (Roche Diag-
nostics) and used for western blot.
MTT Assays
Cells were seeded and treated the following day (day 0). Treated cells were
grown for the indicated times, and on the day of the assay, MTT (3-[4,5-dime-
thylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) reagent was added and
values were determined by absorbance at 570 nm on a plate reader (Tecan).
Soft Agar Growth Assays
Plates were coated with agarosemixed with DMEM. Cells were overlaid on the
bottom layer in an agarose (final agarose concentration of 0.2%) DMEMCell Repmixture supplementedwith the indicated therapeutic treatment. After 2 weeks,
viable foci were visualized with MTT reagent. Each well was imaged using an
Alpha Imager, and foci size was determined using NIH-endorsed ImageJ
software.
Mouse In Vivo Experiments
Six- to ten-week-old female MMTV-neu mice were used for this set of
experiments. For the in vivo treatment model, a rodent erbB2/neu-transformed
Balb/c breast tumor cell line, H2N113 (1 3 106), was injected subcutaneously
into both sides of the back of mice. Tumor size was measured with a digital
caliper and calculated using a simple algorithm (3.14 3 length 3 wide 3
height O 6). All animals were housed and bred in a specific pathogen-free
animal facility of the University of Pennsylvania. All the experiments were per-
formed following national, state, and institutional guidelines. Animal protocols
were approved by the University of Pennsylvania Animal Care and Use
Committee.
Flow Cytometry
At 1 day after final treatment, spleens and tumors were collected and single-
cell suspensions made. Cell surface antigens were stained with the antibodies
indicated. Cells were analyzed with FACS LSR (BD Biosciences), and FACS
data were analyzed with FlowJo software (Tree Star).
MDSC Migration Assay
To prepare conditioned medium, H2N113 cells were seeded and cultured until
sub-confluent in culture. Cells were then treated with 7.16.4 and/or IFN-g at
indicated concentrations for 3 days. Then, the supernatants were collected
for the migration assay. Migration of MDSC was measured by the Transwell
system (pore size: 4 mm; Corning). After 3 hr incubations at 37C, the
cells that migrated to bottom layers were collected and subjected to flow
cytometry.
Statistical Consideration
When applicable, statistical analysis was performed by Student’s t test using
Microsoft Excel. At a minimum, data with a p value < 0.05 were deemed signif-
icant. In all cases, experiments shown are representatives that were performed
at least twice.
For the precise materials and methods, see Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.08.044.
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